{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:42:19Z","timestamp":1787697739780,"version":"build-2784847793"},"reference-count":10,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2005]]},"abstract":"<i>Background and Objectives:<\/i> In adult acute lymphoblastic leukaemia (ALL), unlike in childhood ALL, the percentage of long-term remitters and survivors has not improved significantly over the last decades. In the present analysis, we describe a series of adult ALL patients consecutively treated with the same regimen in order to analyse prognostic factors and treatment outcome as well as to define new risk-oriented strategies. <i>Design and Methods:<\/i> From 1990 to 1998, 102 newly diagnosed ALL patients were referred to our division, 83 of them were eligible for the present study. Median age was 31 years (range 13\u201376); 77.1% had B-lineage ALL and 22.9% T-lineage ALL; 36.1% showed associated myeloid markers. All patients received an induction phase treatment, consisting of a 4-week cycle with vincristine, daunorubicin, <i>L<\/i>-asparaginase and desametasone; the consolidation phase included cyclophosphamide, cytarabine, 6-mercaptopurine and central nervous system (CNS) prophylaxis, followed by three of months maintenance (methotrexate + 6-mercaptopurine), re-induction (4-week cycle with vincristine, adriamicin, desametasone), and 2-year maintenance with methotrexate + 6-mercaptopurine. <i>Results:<\/i> Complete remission (CR) was achieved in 66 patients (79.5%); 20.5% of patients were resistant. The relapse rate was 60.2%. There were 10 CNS relapses (accounting for 12% of all patients, 15% of all CRs and 20% of all relapses). One patient had an ovarian and 2 had a breast relapse. Eleven patients remained in first continuous CR after chemotherapy. Median overall survival (OS) and disease-free survival (DFS) were 1.8 and 1.0 years, respectively, with a median follow-up of 5.6 years (range 0.3\u201312.1). Initial white blood cell count \u226430 \u00d7 10<sup>9<\/sup>\/l, age <35 years, and time to complete remission \u226440 days were the most significant prognostic factors for OS (p < 0.05). These three characteristics defined a group of patients with a better prognosis (5-year OS: 58%). They represented, however, only 18% in this series of adult patients. <i>Interpretation and Conclusions:<\/i> In our cohort, we were able to define a small subgroup of adult ALL patients with a better outcome. However, the majority of patients is at a high risk of failure when treated with standard protocols. There is a need for new, more active regimens for these patients.<\/jats:p>","DOI":"10.1159\/000084676","type":"journal-article","created":{"date-parts":[[2005,6,22]],"date-time":"2005-06-22T12:20:27Z","timestamp":1119442827000},"page":"234-240","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Outcome of Ph-Negative Acute Lymphoblastic Leukaemia in Adults: A Single Centre Experience"],"prefix":"10.1159","volume":"113","author":[{"given":"Carlo","family":"Castagnola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Caberlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Bonfichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Pascutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Lazzarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2005,6,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199310283291801"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.thj.6200091"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.20.4.1094"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood.V99.3.863"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016%2FS0889-8588%2805%2970190-8"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2141.1997.3613175.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2141.2002.03685.x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2002.07.116"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood.V100.1.153"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2FS1535-6108%2802%2900032-6"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/84676","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/84676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:44:23Z","timestamp":1745466263000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000084676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000084676","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}